Innovative Screening Approaches for Early Detection of MS supports research teams developing and validating practical tests to identify likely MS cases in risk-enriched groups and speed neurological evaluation.
Funder: National Multiple Sclerosis Society
Due Dates: December 16, 2026, 5 p.m. ET (Concept note) | June 2, 2027, 5 p.m. ET (Full proposal)
Funding Amounts: Planning Grants: up to $25,000 for 3 months; Screening Test Awards: up to $5 million for 4 years
Summary: Supports development and validation of practical screening tests to identify likely MS cases within risk-enriched populations and accelerate neurological evaluation.
Key Information: A concept note and Planning Grant stage precede full proposals; postdoctoral, residency, and other mentored trainees cannot serve as PI.
The National Multiple Sclerosis Society’s FIRST-MS initiative—Faster Identification, Recognition, and Screening for Timely MS Diagnosis—supports technologies that shorten the path from early signs of multiple sclerosis to definitive diagnosis and treatment. This global screening-test opportunity funds development and validation of scalable, clinically practical, economical technologies for populations already enriched for MS risk, rather than screening the general population.
Responsive approaches include blood-based biomarkers, retinal and other imaging technologies, digital and physiological measures, AI-assisted interpretation, and multimodal screening platforms. Tests should help identify people who should advance to comprehensive neurological evaluation. FIRST-MS is a product-development initiative: projects should address technical and clinical validation, real-world workflows, regulatory approval, reimbursement, adoption, and health-economic value within an integrated diagnostic pathway.